AR016751A1 - Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo - Google Patents

Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo

Info

Publication number: AR016751A1
Authority: AR; Argentina
Prior art keywords: beta; release; inhibiting; cell; pharmaceutical composition
Prior art date: 1996-11-22

Application number

ARP970105393A

Other languages

English (en)

Spanish (es)

Original Assignee

Athena Neurosciences Inc

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-11-22

Filing date

1997-11-18

Publication date

2001-08-01

1997-11-18 Application filed by Athena Neurosciences Inc, Lilly Co Eli filed Critical Athena Neurosciences Inc

2001-08-01 Publication of AR016751A1 publication Critical patent/AR016751A1/es

Links

150000001875 compounds Chemical class 0.000 title abstract 3
238000000034 method Methods 0.000 title abstract 3
239000008194 pharmaceutical composition Substances 0.000 title abstract 3
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1
208000024827 Alzheimer disease Diseases 0.000 abstract 2
102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 2
108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 2
238000003786 synthesis reaction Methods 0.000 abstract 2

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Psychiatry (AREA)
Pharmacology & Pharmacy (AREA)
Hospice & Palliative Care (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)

ARP970105393A 1996-11-22 1997-11-18 Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo AR016751A1 (es)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US75544296A	1996-11-22	1996-11-22
US80752897A	1997-02-28	1997-02-28
US80852897A	1997-02-28	1997-02-28
US80742797A	1997-02-28	1997-02-28

Publications (1)

Publication Number	Publication Date
AR016751A1 true AR016751A1 (es)	2001-08-01

Family

ID=27505670

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ARP970105393A AR016751A1 (es)	1996-11-22	1997-11-18	Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo

Country Status (21)

Country	Link
EP (1)	EP0942924A2 (id)
JP (1)	JP2001503782A (id)
KR (1)	KR20000069064A (id)
CN (1)	CN1238779A (id)
AR (1)	AR016751A1 (id)
AU (1)	AU5356198A (id)
BR (1)	BR9713400A (id)
CA (1)	CA2267634A1 (id)
CO (1)	CO4910156A1 (id)
CZ (1)	CZ122899A3 (id)
EA (1)	EA199900490A1 (id)
HR (1)	HRP970627A2 (id)
HU (1)	HUP0100270A3 (id)
ID (1)	ID22044A (id)
IL (1)	IL129083A0 (id)
NO (1)	NO992368L (id)
NZ (1)	NZ334690A (id)
PE (1)	PE16999A1 (id)
TR (3)	TR199902938T2 (id)
WO (1)	WO1998022494A2 (id)
YU (1)	YU46097A (id)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE122010000020I1 (de)	1996-04-25	2010-07-08	Prosidion Ltd	Verfahren zur Senkung des Blutglukosespiegels in Säugern
US6191166B1 (en) *	1997-11-21	2001-02-20	Elan Pharmaceuticals, Inc.	Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis
US6635632B1 (en)	1996-12-23	2003-10-21	Athena Neurosciences, Inc.	Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
DE19823831A1 (de)	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
WO1999067219A1 (en) *	1998-06-22	1999-12-29	Elan Pharmaceuticals, Inc.	Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
US6958330B1 (en)	1998-06-22	2005-10-25	Elan Pharmaceuticals, Inc.	Polycyclic α-amino-ε-caprolactams and related compounds
WO1999066934A1 (en) *	1998-06-22	1999-12-29	Elan Pharmaceuticals, Inc.	CYCLIC AMINO ACID COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS
US6552013B1 (en)	1998-06-22	2003-04-22	Elan Pharmaceuticals, Inc.	Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
AU4710199A (en) *	1998-06-22	2000-01-10	Elan Pharmaceuticals, Inc.	Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
DE19828114A1 (de)	1998-06-24	2000-01-27	Probiodrug Ges Fuer Arzneim	Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) *	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19834591A1 (de)	1998-07-31	2000-02-03	Probiodrug Ges Fuer Arzneim	Verfahren zur Steigerung des Blutglukosespiegels in Säugern
US6486350B1 (en)	1998-09-30	2002-11-26	Elan Pharmaceuticals Inc.	Biological reagents and methods for determining the mechanism in the generation of β-amyloid peptide
US6737038B1 (en)	1998-11-12	2004-05-18	Bristol-Myers Squibb Company	Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
TR200101663T2 (tr)	1998-12-10	2001-11-21	F.Hoffmann-La Roche Ag	Pro-kollajen c-proteinaz inhibitörleri
US6723711B2 (en)	1999-05-07	2004-04-20	Texas Biotechnology Corporation	Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US6972296B2 (en)	1999-05-07	2005-12-06	Encysive Pharmaceuticals Inc.	Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
AU4826900A (en) *	1999-05-07	2000-11-21	Texas Biotechnology Corporation	Propanoic acid derivatives that inhibit the binding of integrins to their receptors
DE19926233C1 (de)	1999-06-10	2000-10-19	Probiodrug Ges Fuer Arzneim	Verfahren zur Herstellung von Thiazolidin
DE19940130A1 (de)	1999-08-24	2001-03-01	Probiodrug Ges Fuer Arzneim	Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
AU1569401A (en) *	1999-11-09	2001-06-06	Eli Lilly And Company	Beta-aminoacid compounds useful for inhibiting beta-amyloid peptide release and/or its synthesis
AU2001254763A1 (en)	2000-03-31	2001-10-08	Prosidion Limited	Method for the improvement of islet signaling in diabetes mellitus and for its prevention
WO2001087354A2 (en)	2000-05-17	2001-11-22	Bristol-Myers Squibb Pharma Company	Use of small molecule radioligands for diagnostic imaging
CN1386118A (zh)	2000-06-01	2002-12-18	布里斯托尔-迈尔斯斯奎布药品公司	作为Aβ蛋白产生抑制剂的被环状琥珀酸酯取代的内酰胺类化合物
FR2832152A1 (fr) *	2001-11-09	2003-05-16	Aventis Pharma Sa	Utilisation de derives de 2-amino-thiazoline comme inhibiteurs de no-synthase inductible
US6432944B1 (en)	2000-07-06	2002-08-13	Bristol-Myers Squibb Company	Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives
GB0016681D0 (en)	2000-07-06	2000-08-23	Merck Sharp & Dohme	Therapeutic compounds
US7132104B1 (en)	2000-10-27	2006-11-07	Probiodrug Ag	Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders
US6890905B2 (en)	2001-04-02	2005-05-10	Prosidion Limited	Methods for improving islet signaling in diabetes mellitus and for its prevention
US7368421B2 (en)	2001-06-27	2008-05-06	Probiodrug Ag	Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
US20030130199A1 (en)	2001-06-27	2003-07-10	Von Hoersten Stephan	Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
DE10150203A1 (de)	2001-10-12	2003-04-17	Probiodrug Ag	Peptidylketone als Inhibitoren der DPIV
AR039059A1 (es) *	2001-08-06	2005-02-09	Sanofi Aventis	Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
FR2840899B1 (fr) *	2002-06-12	2005-02-25	Sanofi Synthelabo	Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique
DE10143840A1 (de) *	2001-09-06	2003-03-27	Probiodrug Ag	Neue Inhibitoren der Dipeptidylpeptidase I
US6844316B2 (en)	2001-09-06	2005-01-18	Probiodrug Ag	Inhibitors of dipeptidyl peptidase I
JP2005526005A (ja)	2001-11-09	2005-09-02	アベンティス・ファーマ・ソシエテ・アノニム	誘導型ｎｏシンターゼの阻害剤としての２−アミノ−チアゾリン誘導体及びその使用
SK3622004A3 (sk)	2002-02-28	2005-02-04	Prosidion Limited	Inhibítory DPIV na báze glutaminylu
SG159388A1 (en) *	2003-01-08	2010-03-30	Chiron Corp	Antibacterial agents
JP4806628B2 (ja)	2003-05-05	2011-11-02	プロビオドルグエージー	グルタミニルシクラーゼ阻害剤
NZ568459A (en)	2003-05-05	2009-06-26	Probiodrug Ag	Use of effectors of glutaminyl and glutamate cyclases
US20060287246A1 (en) *	2003-09-24	2006-12-21	Shinji Yoneda	Remedy for eye diseases accompanied by optic nerve injuries
CA2542419C (en)	2003-10-15	2013-06-04	Probiodrug Ag	Use of glutamyl cyclase inhibitors in the treatment of familial british dementia and familial danish dementia
CA2934114A1 (en)	2007-06-12	2008-12-18	Achaogen, Inc.	Antibacterial agents
EP2062909A1 (en) *	2007-11-21	2009-05-27	SOLVAY (Société Anonyme)	Peptide production and purification process
BG110141A (en)	2008-05-23	2009-12-31	"Софарма" Ад	GALANTAMINE DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE
EP2847168A1 (en)	2012-05-10	2015-03-18	Achaogen, Inc.	Antibacterial agents
WO2017004560A1 (en) *	2015-07-02	2017-01-05	The Regents Of The University Of California	Methods and compositions for amyloid aggregates
US20240010642A1 (en) *	2021-01-05	2024-01-11	Southern Research Institute	Modulators of programmed death-ligand-1
WO2024076635A2 (en) *	2022-10-05	2024-04-11	Buck Institute For Research On Aging	Suppressors of site iq electron leak and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUT62312A (en) *	1990-03-05	1993-04-28	Cephalon Inc	Process for producing chymotrypsin-like proteases and their inhibitors
WO1995013084A1 (en) *	1992-05-11	1995-05-18	Miles Inc.	Cathepsin d is an amyloidogenic protease in alzheimer's disease
NZ264143A (en) *	1993-08-09	1996-11-26	Lilly Co Eli	Use of an aspartyl protease inhibitor to inhibit beta-amyloid peptide production
AU687449B2 (en) *	1993-10-01	1998-02-26	Aventis Inc.	Inhibitors of beta-amyloid protein production
US5804560A (en) *	1995-01-06	1998-09-08	Sibia Neurosciences, Inc.	Peptide and peptide analog protease inhibitors
US6017887A (en) *	1995-01-06	2000-01-25	Sibia Neurosciences, Inc.	Peptide, peptide analog and amino acid analog protease inhibitors
JPH11506923A (ja) *	1995-06-06	1999-06-22	アセナニューロサイエンシーズ，インコーポレイテッド	新しいカテプシンならびにその阻害のための方法および組成物

1997
- 1997-11-18 AR ARP970105393A patent/AR016751A1/es not_active Application Discontinuation
- 1997-11-19 HR HR08/808,528A patent/HRP970627A2/hr not_active Application Discontinuation
- 1997-11-20 PE PE1997001056A patent/PE16999A1/es not_active Application Discontinuation
- 1997-11-21 KR KR1019997004486A patent/KR20000069064A/ko not_active Withdrawn
- 1997-11-21 CZ CZ991228A patent/CZ122899A3/cs unknown
- 1997-11-21 JP JP52375698A patent/JP2001503782A/ja active Pending
- 1997-11-21 EP EP97950601A patent/EP0942924A2/en not_active Withdrawn
- 1997-11-21 BR BR9713400-7A patent/BR9713400A/pt not_active IP Right Cessation
- 1997-11-21 TR TR1999/02938T patent/TR199902938T2/xx unknown
- 1997-11-21 NZ NZ334690A patent/NZ334690A/en unknown
- 1997-11-21 AU AU53561/98A patent/AU5356198A/en not_active Abandoned
- 1997-11-21 IL IL12908397A patent/IL129083A0/xx unknown
- 1997-11-21 CO CO97068215A patent/CO4910156A1/es unknown
- 1997-11-21 CN CN97199803A patent/CN1238779A/zh active Pending
- 1997-11-21 TR TR1999/02937T patent/TR199902937T2/xx unknown
- 1997-11-21 CA CA002267634A patent/CA2267634A1/en not_active Abandoned
- 1997-11-21 YU YU46097A patent/YU46097A/sh unknown
- 1997-11-21 WO PCT/US1997/020804 patent/WO1998022494A2/en not_active Ceased
- 1997-11-21 EA EA199900490A patent/EA199900490A1/ru unknown
- 1997-11-21 ID IDW990394A patent/ID22044A/id unknown
- 1997-11-21 TR TR1999/01133T patent/TR199901133T2/xx unknown
- 1997-11-21 HU HU0100270A patent/HUP0100270A3/hu unknown
1999
- 1999-05-14 NO NO992368A patent/NO992368L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
NZ334690A (en)	2001-09-28
AU5356198A (en)	1998-06-10
YU46097A (sh)	2000-10-30
HRP970627A2 (en)	1998-08-31
WO1998022494A2 (en)	1998-05-28
TR199901133T2 (xx)	1999-07-21
IL129083A0 (en)	2000-02-17
EP0942924A2 (en)	1999-09-22
ID22044A (id)	1999-08-26
TR199902937T2 (xx)	2001-01-22
TR199902938T2 (xx)	2002-06-21
HUP0100270A3 (en)	2001-09-28
KR20000069064A (ko)	2000-11-25
NO992368D0 (no)	1999-05-14
CA2267634A1 (en)	1998-05-28
EA199900490A1 (ru)	2000-02-28
JP2001503782A (ja)	2001-03-21
NO992368L (no)	1999-06-21
CN1238779A (zh)	1999-12-15
HUP0100270A2 (hu)	2001-08-28
CZ122899A3 (cs)	1999-10-13
PE16999A1 (es)	1999-02-19
WO1998022494A3 (en)	1998-11-26
CO4910156A1 (es)	2000-04-24
BR9713400A (pt)	2000-01-25

Legal Events

Date	Code	Title	Description
2005-02-21	FA	Abandonment or withdrawal

Publication	Publication Date	Title
BR9713400A (pt)	2000-01-25	Processos e compostos para inibir liberação de peptìdeo beta-amilóide e/ou sua sìntese.
BR9714517A (pt)	2000-07-04	Cicloalquila, lactama, lactona e compostos correlatos, composições farmacêuticas compreendendo os mesmos e processos para inibir liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
ID21956A (id)	1999-08-19	Asam n-(aril dan atau heteroarilasetil) amino ester, komposisi farmasi yang mengandungnya, dan metoda untuk menghambat pelepasan betha-amiloid peptida dan atau sintesanya dengan menggunakan senyawa tersebut
ES2178000T3 (es)	2002-12-16	Composiciones y metodos para tratar infecciones usando analogos de indolicidina.
BR0115427A (pt)	2003-10-07	Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, e para prevenir a doença e o progresso da doença de alzheimer, e, uso de um composto
MX9505182A (es)	1997-02-28	Composicion terapeutica para aplicacion topica, que contiene un antagonista de la substancia p.
BR9502707A (pt)	1996-06-04	Composto composição farmacêutica e método para o tratamento de uma afecção
ES2176600T3 (es)	2002-12-01	Derivado de la propiofenona y procedimientos para su preparacion.
BG101841A (bg)	1998-04-30	Инхибитори на клетъчна адхезия
NO994016L (no)	1999-10-18	Heterocykliske forbindelser og deres anvendelse for inhibering av <beta>amyloidpeptid
BG104599A (en)	2001-03-30	Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
TR199701073T1 (xx)	1998-02-21	Protein kinaz C inhibit�rleri.
NZ223400A (en)	1990-08-28	Dental composition containing kappa-caseino-glycopeptides
BR9808429A (pt)	2000-05-23	Composição farmacêutica e processo para a sua preparação.
BR9811099A (pt)	2002-05-14	Inibidores de urocinase
BRPI0113286B8 (pt)	2021-05-25	pirazóis substituídos e composição farmacêutica compreendendo os mesmos.
BR0008922A (pt)	2002-01-15	Compostos úteis como agentes antiinflamatórios
PT735890E (pt)	2002-09-30	Misturas de 2',3'-didesoxi-inosina e hidroxicarbamida para inibicao da disseminacao retroviral
MX9710252A (es)	1998-03-31	Utilizacion de al menos un peptido en una composicion cosmetica o para la preparacion de un medicamento.
ATE273690T1 (de)	2004-09-15	Zusammensetzung zur hautdesinfizierung
BR9913072A (pt)	2001-05-15	Sistemas de anel azacìclico, composição farmacêutica, e, processo para induzir a analgesia
ES2221950T3 (es)	2005-01-16	Dihidrobenzofurano y compuestos relacionados utiles como agentes anti-inflamatorios.
ES2170143T3 (es)	2002-08-01	Composiciones que comprenden halofantrina en una forma especial.
ES2124983T3 (es)	1999-02-16	Utilizacion de un antagonista de substancia p para el tratamiento de las manchas rojas cutaneas de origen neurogeno.
AR004326A1 (es)	1998-11-04	Utilizacion de al menos un antagonista de tnf-alfa, composicion cosmetica, farmaceutica o dermatologica que contiene dicho antagonista y procedimiento detratamiento cosmetico empleando dicho antagonista.